MBRX News and Press, Moleculin Biotech Inc. From 09/10/20

HOUSTON , Sept. 10, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will...

HENDERSON, Nev. , Sept. 9, 2020 /PRNewswire/ -- BRK, Inc. (the "Company") (OTC: BRKK) wishes to inform its shareholders that as part of its expansion onto Europe and the CIS, it has retained the services of Mr. Archil Kublashvili, who has numerous contacts at the C-suite level amon...

HOUSTON , Sept. 9, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it successfully comple...

The following slide deck was published by Moleculin Biotech, Inc. in conjunction with this Read more ...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...

HOUSTON , Aug. 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp , Chairman and Chief Exec...

Moleculin Biotech (NASDAQ: MBRX ) : Q2 GAAP EPS of -$0.17 misses by $0.08 . Cash and cash equivalents of $16.7M. Press Release More news on: Moleculin Biotech, Inc., Earnings news and commentary, Healthcare stocks news, ,

HOUSTON , Aug. 12, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced its financial results for the quarter ende...

HOUSTON , July 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a recent publication b...

Moleculin Biotech (NASDAQ: MBRX ) rises  ~35%  PM in reaction to  independent laboratory testing that confirms antiviral activity of WP1122 against coronavirus. More news on: Moleculin Biotech, Inc., Healthcare stocks news, Stocks on the move, Read more ...